The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Use of mutational profiling of metastatic ER+/HER2- breast cancers and the coexistence of KRAS, MET, BRAF, and FGFR3 with PIK3CA mutations.
Debora Fumagalli
No relevant relationships to disclose
Roberto Salgado
No relevant relationships to disclose
Carmen Criscitiello
No relevant relationships to disclose
Lina Pugliano
No relevant relationships to disclose
Ioanna Laios
No relevant relationships to disclose
Timothy Wilson
Employment or Leadership Position - Genentech/Roche
Denis Larsimont
No relevant relationships to disclose
Martine J. Piccart-Gebhart
No relevant relationships to disclose
Stefan Michiels
No relevant relationships to disclose
Mark Lackner
Employment or Leadership Position - Genentech/Roche
Christos Sotiriou
No relevant relationships to disclose
Sherene Loi
No relevant relationships to disclose